Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm Phase II Study of HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients With KRAS G12D Mutations

NCT06770452 is registered in ClinicalTrials.gov with Zhejiang University as lead sponsor.

NCT NCT06770452
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06770452 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm Phase II Study of HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients With KRAS G12D Mutations
Lead sponsor
Zhejiang University
Phase
Phase 2
Overall status
Recruiting
Start date
March 25, 2025
Completion date
February 1, 2028
Enrollment
133 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic carcinoma